Orthopaedic Surgery - Bisphosphonates

Basics

Bisphosphonates are medications that reduce bone resorption by suppressing osteoclast activity.

They are commonly used in the treatment of osteoporosis, metastatic bone disease, Paget disease of bone, and malignancy-associated hypercalcemia.

Bisphosphonates can be administered either orally or intravenously, depending on the clinical indication, patient factors, and specific medication being used.

Oral Bisphosphonates

Commonly used oral bisphosphonates include alendronate, risedronate, and ibandronate.

These agents are frequently prescribed for osteoporosis and other conditions characterized by excessive bone turnover.

Because oral bisphosphonates can irritate the upper gastrointestinal tract, specific administration instructions are important.

Intravenous Bisphosphonates

Frequently used intravenous agents include zoledronate and pamidronate.

Intravenous therapy is particularly useful in patients with metastatic bone disease, multiple myeloma, malignancy-related hypercalcemia, or those who cannot tolerate oral treatment.

Epidemiology and Clinical Use

Patients with metastatic bone disease or multiple myeloma often have increased osteoclast-mediated bone destruction.

As a result, most such patients receive therapy that suppresses osteoclast function, either with a bisphosphonate or another antiresorptive agent such as denosumab, which inhibits osteoclast formation, function, and survival.

High Bone-Turnover Disorders

Bisphosphonates are also commonly used in disorders associated with increased bone turnover.

These include osteoporosis, Paget disease, and selected cases of polyostotic fibrous dysplasia.

By reducing osteoclastic activity, these medications can decrease excessive bone resorption and improve skeletal stability.

Risk Factors and Dental Considerations

One of the most important concerns before starting bisphosphonate therapy is poor dental health.

Patients with significant dental disease may be at greater risk of developing osteonecrosis of the jaw, particularly when potent intravenous bisphosphonates are used for prolonged periods.

Pretreatment Dental Evaluation

Before beginning long-term or high-potency bisphosphonate therapy, patients should undergo appropriate dental evaluation.

Any necessary tooth extractions, treatment of active dental infection, or major reconstructive dental procedures should ideally be addressed before therapy begins.

Good oral hygiene and regular dental follow-up remain important during treatment.

Pathophysiology

Bisphosphonates reduce skeletal resorption by interfering with the normal function and survival of osteoclasts, the cells responsible for breaking down bone.

Their action ultimately decreases the rate at which mineralized bone is removed.

Mevalonate Pathway

Many bisphosphonates act by interfering with enzymes in the mevalonate pathway.

Disruption of this pathway impairs intracellular processes required for normal osteoclast function.

This reduces the ability of osteoclasts to adhere to and resorb bone effectively.

Osteoclast Ruffled Border

Active osteoclasts form a specialized ruffled border against the bone surface.

This structure is essential for creating the acidic environment and releasing enzymes required for bone resorption.

Bisphosphonates interfere with this resorptive apparatus and thereby diminish osteoclastic activity.

Osteoclast Apoptosis

Bisphosphonates can also promote apoptosis, or programmed cell death, of osteoclasts.

The resulting reduction in osteoclast number and activity decreases bone turnover and limits further bone loss.

Complications

The adverse effects of bisphosphonate therapy vary according to whether the medication is administered orally or intravenously and according to treatment duration.

Important complications include gastrointestinal irritation, acute systemic reactions, osteonecrosis of the jaw, and atypical femoral fractures.

Gastrointestinal Adverse Effects

The most common complication of oral bisphosphonate therapy is upper gastrointestinal irritation or gastric upset.

Patients may experience dyspepsia, reflux symptoms, esophageal irritation, or abdominal discomfort.

Proper administration helps reduce these complications.

Administration of Oral Bisphosphonates

Oral bisphosphonates should generally be taken on an empty stomach with a full glass of water.

The patient should remain upright after taking the medication, traditionally for approximately 30–60 minutes depending on the specific preparation, to reduce the risk of esophageal irritation.

Food and other medications may interfere with absorption and should be avoided for the recommended period after dosing.

Intravenous Adverse Effects

The most common early adverse effects of intravenous bisphosphonates include fever, bone pain, and muscle aches.

These acute-phase reactions may occur in approximately one-quarter of patients, particularly after an initial infusion.

Symptoms are usually temporary.

Osteonecrosis of the Jaw

One of the most important long-term complications of bisphosphonate therapy is osteonecrosis of the jaw.

This complication is characterized by impaired healing and exposed or necrotic jaw bone, often after dental extraction or other invasive dental treatment.

The risk is particularly relevant in patients receiving high-dose intravenous therapy for malignancy.

Prevention of Jaw Osteonecrosis

Preventive measures include addressing major dental problems before treatment, maintaining good oral hygiene, and obtaining regular dental care.

Patients should inform their dentist that they are receiving bisphosphonate therapy.

Any invasive dental procedure during treatment should be planned carefully.

Atypical Femoral Fractures

Long-term bisphosphonate use is also associated with atypical stress fractures of the femur.

These fractures commonly involve the subtrochanteric or femoral shaft region and may develop gradually because of prolonged suppression of bone remodeling.

Prodromal Symptoms

Before an atypical femoral fracture becomes complete, patients may experience thigh or groin pain during walking or weight-bearing.

This discomfort may precede fracture by weeks or months.

Patients receiving prolonged bisphosphonate therapy should report new persistent thigh or groin pain promptly.

Radiographic Findings

Early radiographs may be normal.

When abnormalities are present, they may include periosteal reaction, cortical thickening, or localized beaking of the lateral femoral cortex.

These findings can represent an incomplete or impending atypical fracture.

Duration of Therapy

Because the risk of atypical femoral fracture increases with prolonged treatment, the need for continued bisphosphonate therapy should be reassessed periodically.

Long-term treatment should be individualized according to the patient’s fracture risk, response to therapy, and potential complications rather than continued automatically.

Drug Holiday Consideration

In selected patients whose fracture risk has fallen after several years of therapy, a temporary bisphosphonate drug holiday may be considered.

The timing and duration depend on the specific medication, bone density, previous fractures, and overall osteoporosis risk.

Patients at very high fracture risk may require continued therapy or an alternative treatment strategy.

Patient Monitoring

Patients receiving bisphosphonates are commonly monitored with serial dual-energy X-ray absorptiometry (DEXA) scans.

DEXA testing provides an estimate of bone mineral density and helps assess the response to osteoporosis treatment over time.

Additional Monitoring

Follow-up should also include assessment for new fractures, changes in height or posture, medication tolerance, dental problems, and symptoms suggestive of atypical femoral fracture.

Persistent thigh or groin pain should prompt further evaluation even when the initial radiograph is normal.

Patient Education

Patients should understand why bisphosphonate therapy has been prescribed and how to take the medication correctly.

Those receiving oral therapy should follow administration instructions carefully to reduce gastrointestinal complications.

Patients should also maintain good dental care and promptly report jaw symptoms, persistent thigh or groin pain, or other new skeletal complaints.

Prognosis

When used appropriately, bisphosphonates can substantially reduce excessive bone resorption and help lower fracture risk in patients with osteoporosis and other high-turnover skeletal disorders.

The benefits of therapy should be balanced against uncommon but potentially important complications, especially during prolonged treatment.

Regular reassessment allows treatment to be adjusted according to changing fracture risk and patient response.